To obtain credit, study the material and complete the CME Posttest and Evaluation as instructed at the end of each activity.
After completing each of these educational activities, you should be able to achieve the objective given in the activity.
Patients with bipolar disorder are likely to present with a variety of symptoms and comorbidities, and children and elderly patients with bipolar disorder require special consideration. Bipolar depression can lower quality of life and substantially impair functioning. However, misdiagnosis of bipolar disorder is very likely because patients frequently fail to report manic episodes as periods of illness, which can often lead to a misdiagnosis of unipolar depression and the use of an incorrect, ineffective, and potentially harmful treatment strategy. These activities were designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on bipolar disorder. There are no prerequisites for participating in this activity.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates each Case and Comment educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest (i.e., any proprietary entity producing health care goods or services consumed by, or used on, patients) occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows:
Dr. Gentil, Chair, is a consultant for Servier, Wyeth, and Eli Lilly; and is a member of the speakers/advisory boards for Wyeth and Pfizer. [article list]
Dr. Ketter, Chair, is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Jazz, Novartis, Solvay, and Wyeth; has received grant/research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Pfizer, Repligen, and Wyeth; has received lecture honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline; and his spouse, Nzeera Ketter, M.D., is an employee of Johnson & Johnson. [article list]
In these Case and Comments, investigational information about pharmaceutical agents may be presented that is outside U.S. Food and Drug Administration-approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled “Disclosure of Off-Label Usage” at the end of each Case and Comment for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
These activities have undergone a 3-tier review process: (1) the entire faculty of the series discussed the content at a peer-review planning session; (2) the Chair reviewed the activities for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activities to determine whether the material is evidence-based and objective.
These Case and Comments are developed from the Seventh International Conference on Bipolar Disorder, which was held June 7–9, 2007, in Pittsburgh, Pa. These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., in conjunction with the International Conference on Bipolar Disorder, pursuant to educational grants from Eli Lilly and Company, Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc, and Pfizer Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporters.
 |
|
| - Chairs - Valentim Gentil, MD, PhD Joseph R. Calabrese, MD Terence A. Ketter, MD |
|
| Project Assistants | Anna M. Esquivel, MA Ariel A. Britton, MA E. Alice Leslie, BA Julie L. Hoffman, MFA Aaron Worcester, BA |
| Project Associates | Anna Acerra, BA Sally A. Elliott, BA Andrew J. Gienapp, BA |
| Project Manager | Kathryn Maceri, BA |
| Electronic Media Manager | F. Grant Whittle, PhD |
| Managing Director | Jane B. Eckstein, MA |
| Associate CME Director | Jennifer G. Alessi, MA |
| Assistant CME Director | Susan K. Beaton, BS |
| CME Editor | Becky Brown Derych, MA |
| CME Coordinator | Diane Brunner |
| External CME Advisory Board | |
Chair Michael H. Ebert, MD Vice Chair Richard C. Shelton, MD |
|
E. Sherwood Brown, PhD, MD Stephanie Cavanaugh, MD Lawrence J. Cohen, PharmD Larry Culpepper, MD, MPH John M. Downs, MD Alan J. Gelenberg, MD |
Paul King, MD Joseph A. Lieberman, III, MD Elizabeth H. B. Lin, MD Frank W. Ling, MD J. Sloan Manning, MD Meir Steiner, MD, PhD |
© 2007 Physicians Postgraduate Press, Inc. |
|
Psychiatrist.com Home
Keyword Search